+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 2 Diabetes Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Type 2 Diabetes Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Type 2 Diabetes Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666390
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Type 2 Diabetes Drugs Market grew from USD 77.07 billion in 2024 to USD 84.07 billion in 2025. It is expected to continue growing at a CAGR of 8.91%, reaching USD 128.67 billion by 2030.

Over the past decade, the treatment paradigm for type 2 diabetes has shifted dramatically as novel therapies and delivery technologies emerge to meet the needs of an expanding patient population. Amid rising prevalence, demographic diversity and evolving regulatory frameworks, industry stakeholders must navigate a landscape defined by intense competition and rapid innovation. This introduction provides a concise overview of the therapeutic ecosystem, underscoring the critical drivers of change-from the integration of digital health platforms to the advancement of combination regimens and biologic agents. By situating current developments within broader public health imperatives, it highlights key imperatives for manufacturers, payers and healthcare providers aiming to optimize outcomes and manage costs. As precision medicine and patient-centric care models take center stage, understanding the strategic intersections between product innovation, policy shifts and market access considerations becomes essential. This section establishes the context for a deeper exploration of transformative shifts, tariff impacts, segmentation dynamics, regional nuances and competitive positioning in subsequent sections. By aligning on these foundational insights, executives can better anticipate emerging opportunities and prepare for disruptive forces reshaping the type 2 diabetes therapeutics market.

Transformative Innovations and Care Model Evolution

The type 2 diabetes drug landscape has undergone transformative shifts driven by breakthroughs in mechanism-based therapies and evolving patient care models. GLP-1 receptor agonists moved from niche options to frontline therapies as real-world evidence validated their cardiovascular and weight management benefits. Meanwhile, SGLT2 inhibitors expanded their clinical indication beyond glycemic control to address heart failure and renal protection, signaling a move toward multi-system disease management. At the same time, fixed-dose combination products streamlined regimens by pairing complementary oral agents, increasing adherence in complex treatment plans. Biologic and gene therapy approaches are also gaining traction, promising precision targeting at the molecular level. Beyond pharmacology, digital therapeutics and remote monitoring platforms have integrated seamlessly with drug regimens, enabling data-driven titration and personalized dosing. Reimbursement frameworks adapted to value-based models now reward outcomes over volume, incentivizing therapies with demonstrated long-term health improvements. As these shifts converge, they not only redefine the standard of care but also reshape competitive dynamics, supply chain considerations and stakeholder collaboration. Consequently, agility in product development and strategic partnerships has become paramount for maintaining leadership in this rapidly evolving market.

Assessing the 2025 US Tariff Impact on Cost and Supply

In 2025, the imposition of revised US tariffs on imported active pharmaceutical ingredients and finished drug products introduced new cost pressures across the value chain. Manufacturers reliant on global supply networks experienced higher input costs for key intermediates, particularly those sourced from Asia-Pacific facilities. As a result, downstream pricing strategies came under scrutiny, with some firms reallocating production to domestic sites to mitigate duties, while others renegotiated supplier contracts to preserve gross margins. Payers responded by tightening formulary placements and demanding greater evidence of cost-effectiveness, prompting manufacturers to accelerate real-world outcomes studies. Furthermore, increased tariffs on innovative excipients and specialized packaging materials disrupted just-in-time manufacturing models, leading some contract manufacturers to diversify vendor portfolios. Despite these headwinds, strategic players leveraged scale and integrated manufacturing to absorb a portion of the tariff burden, using volatility as an opportunity to reinforce supply resilience. Moving forward, continuous monitoring of policy updates and proactive engagement with regulatory bodies will be critical, ensuring that pricing, sourcing and distribution strategies align with an evolving trade environment.

Comprehensive Segmentation Analysis Uncovers Targeted Opportunities

A granular view of market segmentation reveals nuanced opportunities across product, demographic, channel and technological dimensions. Based on product type, the combination drugs segment encompasses both fixed-dose combinations and branded offerings such as Glucovance and Janumet, reflecting a trend toward regimen simplification; the injectable drugs category spans amylin analogs, GLP-1 receptor agonists and various insulin formulations, highlighting the momentum behind biologic and peptide therapies; oral antidiabetics, including biguanides, DPP-4 inhibitors, SGLT2 inhibitors, sulfonylureas and thiazolidinediones, continue to serve as foundational therapies with evolving adjunctive roles. Patient demographics stratify use across adult, geriatric and pediatric cohorts, each presenting distinct adherence challenges and safety profiles. Distribution channels range from clinics and hospital pharmacies to online and retail outlets, illustrating the importance of omnichannel engagement. Mechanism of action segmentation covers glucagon secretion inhibitors, glucose absorption inhibitors, insulin secretagogues and insulin sensitizers, underscoring the shift toward targeted metabolic interventions. Therapy type differentiates between combination therapy and monotherapy pathways, shaping prescribing patterns. End-user categories-healthcare professionals, patients and research and academic institutions-drive demand for educational initiatives and real-world evidence. Methods of administration include inhalation, injection and oral routes, while technological innovation spans biologic drugs, gene therapy agents and nanotechnology-based delivery systems. By aligning portfolio strategies with these multidimensional insights, companies can tailor offerings to unmet needs and emerging care models.

Regional Market Variations Shape Strategic Priorities

Regional dynamics further influence competitive priorities and adoption trajectories. In the Americas, high prevalence rates, established reimbursement frameworks and advanced digital health infrastructure accelerate uptake of next-generation therapies and combination regimens. Conversely, Europe, Middle East & Africa present a heterogeneous landscape where centralized health technology assessment bodies drive value-based adoption, and emerging markets grapple with access gaps and cost containment pressures. In the Asia-Pacific region, demographic shifts, rising urbanization and increasing incidence rates fuel demand for both traditional oral agents and innovative biologics, although supply chain complexity and regulatory variability pose execution challenges. Consequently, successful market participants deploy regionally tailored strategies, balancing global clinical evidence with localized pricing, distribution and stakeholder engagement plans. These nuanced approaches ensure that therapies resonate with diverse healthcare ecosystems and patient populations.

Competitive Landscape and Pipeline Differentiation

Leading pharmaceutical and biotech players have intensified efforts to fortify their pipelines and expand market share through innovation and collaboration. Abbott Laboratories leverages digital glucose monitoring to complement therapeutic regimens, whereas Amgen Inc. channels investment into monoclonal antibody approaches for metabolic modulation. AstraZeneca focuses on next-generation GLP-1 receptor agonists and combination therapies, while Bayer Inc. integrates cardiovascular protection data to differentiate its offerings. The Boehringer Ingelheim and Eli Lilly partnership underscores the power of co-development in delivering optimized fixed-dose combinations. Bristol-Myers Squibb explores novel immunometabolic pathways, and Chugai Pharmaceutical pioneers antibody-based targets. DAIICHI SANKYO emphasizes gene therapy platforms, alongside Eli Lilly and Company’s continued leadership in insulin analog innovations. GSK plc bolsters its SGLT2 inhibitor portfolio, and Johnson & Johnson expands delivery through advanced pen and pump systems. Merck & Co., Inc. advances research at the intersection of immunology and metabolism, Novartis AG explores nanotechnology carriers, Peptron develops next-generation peptide therapies, Pfizer Inc. refines dual-mechanism oral agents, and the Sanofi Group remains a stalwart in long-acting insulins and strategic partnerships. This competitive mosaic highlights the importance of diversified pipelines, strategic alliances and technology investments in sustaining growth.

Actionable Strategies for Sustained Market Leadership

Industry leaders must adopt a multipronged agenda to thrive amid intensifying competition and regulatory evolution. First, accelerating real-world evidence generation and publishing robust outcomes studies will support premium pricing and formulary access. Second, diversifying manufacturing footprints by establishing modular production hubs and near-shore partnerships will enhance supply chain resilience against tariff fluctuations. Third, investing in digital health ecosystems-including remote monitoring, artificial intelligence-driven titration algorithms and patient engagement platforms-will strengthen adherence and reduce total cost of care. Fourth, prioritizing adaptive clinical trial designs and platform studies will shorten time-to-market for combination and precision therapies. Fifth, co-development alliances across biotech, academia and technology firms will unlock synergies in novel drug discovery and delivery. Finally, embracing value-based contracting and risk-sharing agreements with payers will align incentives and facilitate uptake of high-cost therapies. By executing on these recommendations, organizations can secure market leadership and deliver meaningful improvements in patient outcomes.

Synthesis of Market Dynamics and Value Creation Imperatives

In summary, the type 2 diabetes therapeutics market is transforming through innovative mechanisms of action, personalized care models and evolving policy landscapes. Tariff changes and regional disparities have introduced new complexities, while granular segmentation insights reveal targeted growth areas across product types, demographics and technologies. Leading companies differentiate through diversified pipelines, strategic partnerships and investments in digital and manufacturing capabilities. By aligning on data-driven strategies, fostering collaborative ecosystems and embracing value-based access models, stakeholders can navigate the shifting terrain and deliver superior patient outcomes. These coordinated efforts will define the next era of diabetes management and position organizations for long-term success.

Market Segmentation & Coverage

This research report categorizes the Type 2 Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Combination Drugs
    • Fixed-Dose Combinations
    • Glucovance
    • Janumet
  • Injectable Drugs
    • Amylin Analogs
    • Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
    • Insulins
  • Oral Antidiabetics
    • Biguanides
    • Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    • Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
    • Sulfonylureas
    • Thiazolidinediones
  • Adult
  • Geriatric
  • Pediatric
  • Clinics
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Glucagon Secretion Inhibitors
  • Glucose Absorption Inhibitors
  • Insulin Secretagogues
  • Insulin Sensitizers
  • Combination Therapy
  • Monotherapy
  • Healthcare Professionals
  • Patients
  • Research And Academic Institutions
  • Inhalation
  • Injection
  • Oral
  • Biologic Drugs
  • Gene Therapy Drugs
  • Nanotechnology-Based Drugs

This research report categorizes the Type 2 Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Type 2 Diabetes Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca
  • Bayer Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Peptron
  • Pfizer Inc.
  • Sanofi Group

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Type 2 Diabetes Drugs Market, by Product Type
8.1. Introduction
8.2. Combination Drugs
8.2.1. Fixed-Dose Combinations
8.2.2. Glucovance
8.2.3. Janumet
8.3. Injectable Drugs
8.3.1. Amylin Analogs
8.3.2. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
8.3.3. Insulins
8.4. Oral Antidiabetics
8.4.1. Biguanides
8.4.2. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
8.4.3. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
8.4.4. Sulfonylureas
8.4.5. Thiazolidinediones
9. Type 2 Diabetes Drugs Market, by Patient Demographics
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Type 2 Diabetes Drugs Market, by Distribution Channels
10.1. Introduction
10.2. Clinics
10.3. Hospital Pharmacies
10.4. Online Pharmacies
10.5. Retail Pharmacies
11. Type 2 Diabetes Drugs Market, by Mechanism Of Action
11.1. Introduction
11.2. Glucagon Secretion Inhibitors
11.3. Glucose Absorption Inhibitors
11.4. Insulin Secretagogues
11.5. Insulin Sensitizers
12. Type 2 Diabetes Drugs Market, by Therapy Type
12.1. Introduction
12.2. Combination Therapy
12.3. Monotherapy
13. Type 2 Diabetes Drugs Market, by End-User
13.1. Introduction
13.2. Healthcare Professionals
13.3. Patients
13.4. Research And Academic Institutions
14. Type 2 Diabetes Drugs Market, by Method Of Administration
14.1. Introduction
14.2. Inhalation
14.3. Injection
14.4. Oral
15. Type 2 Diabetes Drugs Market, by Technology
15.1. Introduction
15.2. Biologic Drugs
15.3. Gene Therapy Drugs
15.4. Nanotechnology-Based Drugs
16. Americas Type 2 Diabetes Drugs Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Type 2 Diabetes Drugs Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Type 2 Diabetes Drugs Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Abbott Laboratories
19.3.2. Amgen Inc.
19.3.3. AstraZeneca
19.3.4. Bayer Inc
19.3.5. Boehringer Ingelheim International GmbH
19.3.6. Bristol-Myers Squibb Company
19.3.7. Chugai Pharmaceutical Co., Ltd.
19.3.8. DAIICHI SANKYO COMPANY, LIMITED
19.3.9. Eli Lilly and Company
19.3.10. GSK plc
19.3.11. Johnson & Johnson Services, Inc.
19.3.12. Merck & Co., Inc.
19.3.13. Novartis AG
19.3.14. Peptron
19.3.15. Pfizer Inc.
19.3.16. Sanofi Group
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. TYPE 2 DIABETES DRUGS MARKET MULTI-CURRENCY
FIGURE 2. TYPE 2 DIABETES DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. TYPE 2 DIABETES DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TYPE 2 DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCOVANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY JANUMET, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCAGON SECRETION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCOSE ABSORPTION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN SECRETAGOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN SENSITIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GENE THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY NANOTECHNOLOGY-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 88. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 89. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 90. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 91. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 92. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 93. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 95. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 98. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 105. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 146. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 147. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 148. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 149. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 150. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 151. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 152. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 157. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 158. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 159. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 160. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 161. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 162. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 163. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 168. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 169. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 170. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 171. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 179. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 180. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 181. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 182. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 183. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 184. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 185. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 190. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 191. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 192. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 193. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 194. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 195. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 201. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 202. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 203. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 204. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 205. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 206. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 207. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 210. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 212. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 213. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 214. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 215. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 216. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 217. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 224. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 225. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 226. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 227. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 228. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 229. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 236. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 237. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 238. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 239. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 240. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 245. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 246. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 247. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 248. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 249. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 250. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 251. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 252. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 254. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 256. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 257. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 258. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 259. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 260. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 261. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 262. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 277. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 279. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 280. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 281. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 282. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 283. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 284. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 285. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 286. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 288. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 290. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 294. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 295. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 296. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 297. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 299. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 301. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 302. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 303. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 304. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 305. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 306. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 307. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 310. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 312. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 313. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 314. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 315. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 316. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 317. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 318. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 319. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 321. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 322. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 323. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 324. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 325. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY

Companies Mentioned

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca
  • Bayer Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Peptron
  • Pfizer Inc.
  • Sanofi Group

Methodology

Loading
LOADING...

Related Topics

Related Reports

Diabetes Drugs Market by Product, Application, Distribution Channel - Global Forecast 2025-2030 - Product Image

Diabetes Drugs Market by Product, Application, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Type 1 Diabetes Drug Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Type 1 Diabetes Drug Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Type (Type 1, Type 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Type (Type 1, Type 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 100 Pages
  • Global
From
Diabetes Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Diabetes Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Image

Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • 1400 Pages
  • Global
From

About the Type 2 Diabetes Drug Market

The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors. Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.